GSK plc (GSK)
GSK plc (GSK) is a healthcare company (drug manufacturers - general) based in the United Kingdom. The share price is $49.48, down 1.84% on the day, which values the company at $99.18B. Price as of 17 Nov 2026, 17:16 UTC, from Yahoo Finance.
Key facts
- Share price
- $49.48−1.84% today
- Market value
- $99.18B
- P/E ratio
- 17.2×last 12 months
- Forward P/E
- 10.0×
- Dividend yield
- 1.37%
- Funk Score
- 73/100
- 200-week average
- $41.7818% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
GSK plc in more detail
GSK trades at 17.2× its last twelve months' earnings, 10.0× next year's expected earnings, 3.0× sales. It sits 18% above its 200-week average of $41.78.
Its Funk Score is 73 out of 100 (financial strength 7.2, profitability 8.3, growth 6.4, each out of 10).
In its favour: Strong Piotroski score; High return on invested capital.
11 of the superinvestors tracked here hold GSK, including Dodge & Cox team (1.1% of the portfolio), Thomas Kahn (0.9% of the portfolio), Primecap team (0.8% of the portfolio).
Superinvestors holding GSK
11 of the investors tracked here report a position in their latest 13F filing.
- Dodge & Cox team Dodge & Cox1.12% of portfolio · $2.1B · trimmed · Q3 2026
- Thomas Kahn Kahn Brothers0.91% of portfolio · $5.5M · trimmed · Q3 2026
- Primecap team Primecap Management0.75% of portfolio · $1.2B · added · Q3 2026
- Charles Brandes (founder) Brandes Investment Partners0.50% of portfolio · $72.2M · added · Q3 2026
- Ken Fisher Fisher Investments0.49% of portfolio · $1.7B · trimmed · Q3 2026
- Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)0.41% of portfolio · $188.7M · added · Q3 2026
- Tweedy, Browne team Tweedy, Browne Company0.30% of portfolio · $3.7M · trimmed · Q3 2026
- Steve Cohen Point72 Asset Management0.21% of portfolio · $139.1M · new · Q2 2026
- Howard Gleicher Aristotle Capital Management0.12% of portfolio · $53.9M · trimmed · Q3 2026
- Murray Stahl Horizon Kinetics0.01% of portfolio · $1.1M · trimmed · Q3 2026
- Richard Pzena Pzena Investment Management0.00% of portfolio · $1.4M · added · Q3 2026
Health Care companies of similar size
- Vertex PharmaceuticalsVRTX
- MedtronicMDT
- Bristol-Myers SquibbBMY
- StrykerSYK
- McKessonMCK
- SanofiSNY
- ModernaMRNA
- CVS HealthCVS
- HCA HealthcareHCA
- Regeneron PharmaceuticalsREGN
- Elevance HealthELV
- Cigna GroupCI
Side by side:GSK vs HCA (GSK plc vs HCA Healthcare)GSK vs CVS (GSK plc vs CVS Health)GSK vs MRNA (GSK plc vs Moderna)GSK vs REGN (GSK plc vs Regeneron Pharmaceuticals)GSK vs SNY (GSK plc vs Sanofi)
All health care companies by market valueLargest companies in the United KingdomAll stocks A–Z
GSK plc (GSK): questions and answers
What is GSK's P/E ratio?
GSK plc trades at 17.2× its last twelve months' earnings and 10.0× next year's expected earnings.
What is GSK's PEG ratio?
GSK plc's PEG ratio is 6.47 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is GSK plc's market cap?
GSK plc is valued at $99.18B at a share price of $49.48.
Is GSK above its 200-week moving average?
Yes. GSK is 18.4% above its 200-week average of $41.78. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is GSK plc growing?
Over the last three fiscal years GSK plc's revenue grew 3.7% a year and its earnings per share -27.6% a year.
Does GSK pay a dividend?
Yes. GSK plc's dividend yield is 1.37%, or $1.83 a share a year, paying out 63% of earnings.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “GSK plc (GSK) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/GSK
Underlying data: Yahoo Finance; company filings with the SEC.